Pulmonary arterial hypertension (PAH) is a multifactorial disease characterized by sustained elevation of pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP) leading to right ventricular (RV) failure and death (Fig. 1). Despite our improved understanding of the mechanisms involved and treatment, current therapies focusing on vasodilators fail to reverse vascular remodeling and long-term survival remains poor, underscoring the need to identify new therapeutic targets.1 On the basis of many points of overlap, among which deregulated cellular metabolism, sustained proliferation, and escape from apoptosis are the most predominant, PAH has emerged as a cancer-like disease (Fig. 2), providing new therapeutic perspectives for scientists.2,3

Hyperproliferative mechanisms in PAH cells

Growth factors and inflammatory mediators

A wide array of growth factors, cytokines, and chemokines has been documented to promote cancer and PAH development.4,5,6 Of these factors, interleukin 6 (IL-6) and platelet-derived growth factor (PDGF) have been the most studied. Infiltration of inflammatory cells such as macrophages, mast cells, leukocytes, and lymphocytes in pulmonary vascular lesions is a major hallmark of PAH. Indeed, inflammatory cells are a major source of pro-inflammatory mediators responsible for the accumulation of extracellular matrix components and directly implicated in the exaggerated proliferation of resident pulmonary artery (PA) cells. Therefore, elevated circulating levels of the pro-inflammatory cytokines including IL-6, monocyte chemotactic protein 1 (MCP-1), and tumor necrosis factor alpha (TNFα) have been found in PAH patients, and most of them correlate with a worse clinical outcome.7,8 The pathogenic relevance of IL-6 is illustrated by genetic studies in mice
showing that knockout mice are protected against chronic hypoxia-induced pulmonary hypertension (PH), whereas IL-6 over-expressing mice develop PH. Like fibroblast growth factor-2 (FGF2), insulin-like growth factor 1 (IGF-1), and endothelin-1, PDGF also actively participates in mitogenic signaling and thickening of the pulmonary vascular media. The binding of these signaling molecules to their receptors activates various interconnected signaling pathways such as MEK/ERK, PI3K/AKT, and JAK/STAT3 to induce cell growth, cell cycle progression, and cell survival (Fig. 3). In view of its implications in cancer progression, STAT3 has also been the focus of much attention.
in PAH. In PA smooth muscle cells (PASMCs) from PAH patients, activation of STAT3 was shown to upregulate expression of proviral integration site for moloney murine leukemia virus-1 (PIM-1), a proto-oncogene with serine/threonine kinase activity regulating various oncogenic pathways. The latter was reported to enhance nuclear factor of activated T-cells (NFAT)-mediated transactivation, leading to inhibition of voltage-gated potassium channels, increases in cytosolic-free calcium concentration, and subsequent stimulation of cell proliferation and contraction (Fig. 3). Consistently, in vivo inhibition of PIM-1 by nebulized siRNA reversed monocrotaline (MCT)-induced PAH in rats and Pim-1 deficient mice are resistant to development of PH. Based on the current knowledge, inhibition of PIM-1 is likely to become an anti-proliferative strategy for patients suffering PAH. To this end, pharmacological inhibitors of PIM-1 currently undergoing evaluation in clinical trials as anticancer agents could be considered in a near future to treat PAH.

High levels of VEGF were found in the plasma of PAH patients and VEGF as well as its receptor (VEGFR2) are robustly expressed in the complex pulmonary arterial lesions of PAH patients. However, somewhat counter-intuitively to the hypothesis that increased VEGF expression contributes to vascular lesions in PAH, treatment of rodents with a VEGF receptor/tyrosine kinase antagonist, Su5416, in combination or not to hypoxia was shown to induce PAH and VEGF overexpression was reported to attenuate the development of hypoxic PH. With these findings, a two-step model can be proposed in which initial blockade of the VEGF pathway increases the susceptibility to PA endothelial cell (PAEC) apoptosis contributing to the selection of apoptosis-resistant cells followed by an increased expression of VEGF by resident cells promoting cellular expansion. In response to growth factors and inflammatory cytokines, activation of the PI3K/AKT and JAK/STAT3 signaling pathways has been reported to converge on the transcription factor Forkhead box protein O1 (FOXO1) to induce its phosphorylation and inhibit its activity through...
nuclear exclusion (Fig. 3). In agreement with studies indicating that FOXO1 functions as a tumor suppressor, abrogation of FOXO1 transcriptional activity in PASMCs was associated with an upregulation of Cyclin B1 and D1 required for cell cycle progression and a reduced expression of p27 that inhibits Cyclin/Cdk complexes. Moreover, in vivo pharmacological inhibition or conditional inactivation of FOXO1 in smooth muscle cells was shown to induce PH, whereas constitutive activation of FOXO1 had the opposite effect.

**mTOR signaling**

The mechanistic target of rapamycin (mTOR) signaling is a pivotal regulator of cellular metabolism, cell proliferation, and survival. mTOR is a serine-threonine kinase that interacts with several proteins to form two independent complexes, mTORC1 (mTOR-Raptor) and mTORC2 (mTOR-Rictor), which have different sensitivity to rapamycin and downstream outputs. The mTORC1 pathway integrates inputs from many cues including growth factors, DNA damage, oxygen availability, amino acids, and energy status to activate ribosomal protein S6 kinase beta-1 (S6K1) and to inhibit eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), leading to enhanced anabolic cell growth and proliferation (Fig. 3). Conversely, mTORC2 mainly responds to growth factors and promotes cell survival due to its regulatory functions in cell proliferation and survival, the mTOR signaling generates considerable interest in the field of cancer and PAH. The importance of the mTORC2 signaling in PAH development was highlighted by in vitro studies demonstrating that Rictor knockdown reduced glycolysis-dependent proliferation and survival of PASMCs, while inhibition of Raptor led to a decrease in cell proliferation without effect on cell survival. Consistently, selective hyperactivation of mTORC1 caused by inactivation of the negative mTORC1 regulator tuberous sclerosis complex 1 gene (TSC1) was sufficient to produce distal PA remodeling and PH in mice, a pathological state fully reversed following rapamycin treatment, emphasizing the relevance of this pathway in PAH.

**Hippo signaling**

The Hippo signaling pathway has recently emerged as an evolutionarily conserved signaling pathway that controls organ size. The backbone of the Hippo pathway consists of a cascade of tumor suppressive kinases mammalian STE20-like protein kinase 1/2 (MST1/2) and large tumor suppressor homolog 1/2 (LATS1/2) that regulate the activity of the downstream effectors yes-associated protein 1 (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ). When the pathway is activated, LATS1/2 directly phosphorylate YAP and TAZ resulting in their cytoplasmic retention and cell growth inhibition (Fig. 3). In recent years, several studies have investigated the possible involvement of this pathway in PAH development and progression. Among these, Kudryashova and collaborators found that in response to mechanical cues or mitogenic factors, human PAH-PASMCs exhibit diminished expression of phospho-LATS1 and consistently YAP nuclear accumulation. To test the requirement of LATS1/YAP in cell proliferation, transfection of PAH-PASMCs with a LATS1 construct mimicking a constitutive phosphorylated state was done demonstrating a rescue of the abnormal pro-proliferative and apoptosis-resistant phenotype of these cells. Furthermore, the authors demonstrated that inactivation of LATS1 was associated with the over-expression and the activation of numerous proteins and pathways known to play a deleterious role in the pulmonary vasculature, including hypoxia inducible factor 1 alpha subunit (HIF-1α) and neurogenic locus notch homolog protein 3 (NOTCH3). Although Hippo signaling serves as a hub in regulating cell proliferation and represents a potential therapeutic target in PAH, the detailed characteristics of YAP/TAZ “oncogenic” properties remain unclear.

**The cellular gatekeeper p53**

Because more than 50% of human cancers contain loss of function mutations in the transcription factor p53, it is recognized as a master tumor suppressor that activates the expression of several genes that promote cell cycle arrest or apoptosis in response to stress. Given its obvious role in cancer, p53 has received attention from the PAH community. Mizuno et al. found that p53 deletion exacerbates hypoxia-induced PH in mice. In agreement with a protective role played by p53 in PH, Mouraret et al. demonstrated that daily intraperitoneal treatment of Nutlin-3a that inhibits p53-murine double minute2 (MDM2) interaction and activates p53 signaling improved PH, right ventricular hypertrophy and distal PA remodeling in mice exposed to chronic hypoxia or Sugen/hypoxia. Moreover, these beneficial effects were not observed in mice deficient for either p53 or p21 (cyclin-dependent kinase inhibitor), pinpointing the critical requirement of p53 stabilization and p21 expression in the Nutlin-3a effects. Taking into account that p53 regulates many cellular processes such as metabolism, autophagy, and DNA repair, further studies are needed to delineate its precise role in PAH development and progression.

**Telomere length maintenance**

Unlimited proliferation is one of the hallmarks of cancer (Fig. 2). During each round of division, normal cells shorten their telomeres (a highly organized and dynamic nucleoproteic structure located at the ends of chromosomes) due to the end replication problems. In cancer cells, reactivation of the reverse transcriptase subunit of telomerase (TERT) stabilizes telomere length and thereby circumvents the senescence program and provides an endless
Adaptive pro-survival mechanisms in PAH cells

Although exposed to stressful conditions, including a pseudo-hypoxic environment characterized by normoxic activation of HIF-1α, inflammation, shear stress, and oxidative stress that jeopardize their survival, PA cells from PAH patients exhibit a pro-proliferative and anti-apoptotic phenotype, indicating that cells have developed cytoprotective responses preserving homeostasis (Fig. 2).

DNA damage in pulmonary arterial hypertension

DNA repair processes are essential for maintenance of genomic integrity. Many DNA damaging events continuously challenge the genome integrity of dividing cells. In order to cope with DNA damage, cells trigger a signaling network termed as DNA damage response (DDR) that senses, signals, and repairs DNA lesions. Successful repair allows cells to continue proliferating. In contrast, unsuccessful DNA repair results in accumulation of DNA damage and activation of programmed cell death. DNA damage and repair have recently been linked to the onset and progression of PAH. It is proposed that in early stages of the disease, persistent stress coupled to inefficient DNA repair mechanisms produces irreversible accumulation of DNA damage, PAEC apoptosis and subsequent selection of apoptosis-resistant, proliferative vascular cells. This is supported by findings showing that reduced bone morphogenetic protein receptor type II (BMPR2) signaling increases vulnerability of PAECs to DNA damage and apoptosis due to reduced expression of breast cancer 1 (BRCA1) and topoisomerase (DNA) II binding protein 1 (TOPBP1), two key players in DNA damaging signaling. Moreover, mice deficient for Ku70, a subunit of the Ku protein complex that plays an essential role in the non-homologous end-joining (NHEJ) pathway for DNA double-strand break (DSB) repair, display lung abnormalities reminiscent of plexiform lesions seen in human PAH. As opposed to the early stages of the disease, sustained activation of the DNA repair machinery was identified as an adaptive response used by PAH cells to counteract the stress-induced DNA damage, allowing them to survive and proliferate and leading to the occlusion of small PA. Indeed, increased expression and activation of the DNA repair protein poly (ADP-ribose) polymerase family, member 1 (PARP-1) due to miR223 downregulation, is a feature of PAH-PASMCs contributing to the cancer-like phenotype of these cells. Importance of PARP-1 in acquired resistance to apoptosis of PAH cells is exemplified by in vivo studies showing that pharmacological inhibition of PARP-1 reversed established PAH in two experimental models. Consistently, expression of the translationally controlled tumor protein (TCTP), implicated in cell growth as well as DNA damage sensing and repair, was identified by proteomic screening as being upregulated in blood outgrowth endothelial cells from BMPR2 mutated PAH patients. Based on these findings, exacerbating DNA damage in remodeled pulmonary arteries, in either exposing cells to DNA damaging agents or inhibiting factors that sense or respond to DNA damage offers a new therapeutic avenue for reversing PAH.

Adaptation of proteostasis network

In response to cellular stress, cancer and PAH cells accumulate misfolded proteins and aggregates, harmful to the cell. To deal with these cytotoxic agents, cells have developed a complex network of protein quality-control mechanisms. Central to these strategies are the activation of molecular chaperones to cope with the increasing number of misfolded proteins and the promotion of their clearance by the ubiquitin-proteasome system (UPS) and autophagy. The coordinated and complementary relationship between these two degradation pathways is exemplified by findings showing that inhibition of proteosomal activities induces autophagy. Increased expression of molecular chaperones represents a defense mechanism against a wide range of proteotoxic conditions by inducing protein refolding or stabilizing new proteins. Heat shock protein 90 (Hsp90) is one of the most thoroughly characterized chaperones, whose over-expression is exploited by many cancers to stabilize numerous and essential pro-survival proteins. As a consequence, and owing to its nodal properties, Hsp90 has been extensively investigated as a target for cancer therapy. As observed in cancer cells, Hsp90 was found to be upregulated in remodeled distal pulmonary arteries of PAH patients. Moreover, inhibition of cytosolic Hsp90 was shown to alleviate PAH progression in the MCT model, as illustrated by lower pulmonary pressure and absence of right ventricular hypertrophy. Nevertheless, since PAH is most frequently diagnosed at late stages when patients already present structural abnormalities, the efficacy and safety of Hsp90 inhibition in experimental models with established PAH remains to be investigated.
Autophagy, a stress-induced catabolic process characterized by the formation of double-membrane vesicles known as autophagosomes in which intracellular protein aggregates and damaged organelles are engulfed, degraded by fusion with lysosomes and recycled to sustain cellular metabolism, has been proposed to mediate apparently contradictory roles in cancer cells in stimulating both cell death and cell survival depending on the context. Although autophagy was repeatedly found to be increased in PAH cells,62–66 its role in PAH also remains uncertain. On the one hand, Long et al. demonstrated that inhibition of autophagy with Chloroquine exerts both preventive and ameliorating effects in the monocrotaline rat model of PAH, a beneficial effect accompanied with preserved BMPR2 expression.68 On the other hand, Lee et al. found that loss of function of the autophagic protein microtubule-associated proteins 1A/1B light chain 3B (LC3B) increases susceptibility to hypoxia-induced pulmonary hypertension.67 Based on these findings, more experimental studies are required before drawing any conclusion on the role of autophagy in both early and late stage of the disease. Intimately linked to autophagy, the UPS is the major mechanism of non-lysosomal proteolysis of intracellular proteins and as such is critical for the proliferation and survival of cancer cells. Based on antitumor activity in a broad range of preclinical cancer models, targeting the UPS has emerged as a rational apoptotic-based approach to reverse pulmonary vascular remodeling in PAH. Although proteasome inhibitors including Bortezomib59,60 and Carfilzomib61 have demonstrated beneficial effects reducing the PA wall thickness, the potential toxicity of these inhibitors remains a strong concern. Since UPS and autophagy cooperate to remove abnormal proteins, coupling autophagy inhibition strategies with proteosomal inhibitors may provide synergistic benefits.

**Metabolic reprogramming and mitochondrial dynamic**

Cancer and PAH cells have been documented to undergo metabolic adaptations (Fig. 2).62–66 In response to hypoxia, endoplasmic reticulum stress, or inflammation, this metabolic reprogramming towards a glycolytic metabolism, known as the Warburg effect, has been shown to provide a selective pro-survival advantage to distal PA cells, irrespective of oxygen availability.63,64,67,68 This metabolic shift driven by HIFs overactivation (through the transcriptional upregulation of glucose transporters, hexokinase, pyruvate dehydrogenase kinase [PDK], and lactate dehydrogenase [LDH]) is directly associated with the hyperpolarization of the mitochondrial membranes. This leads to an increase in the opening threshold of the mitochondria transition pore (a channel through which pro-apoptotic factors move to the cytoplasm), thereby reducing the basal sensitivity to cell death inducers. In addition to augmented glycolysis, cancer and PAH cells rely on other metabolic fuels with increased fatty acid (FA) synthesis and boosted glutamine metabolism to sustain higher proliferation rate and resist to cell death signals.69,70 FA are essential components of biological membranes and are important substrates for energy metabolism. Mice deficient for the metabolic enzyme malonyl-coenzyme A decarboxylase (a key enzyme involved in FA biosynthesis) are resistant to the development of chronic hypoxia-induced PH. Consistently, treatment with trimetazidine (an antianginal drug that shifts metabolism from fatty acid oxidation to glucose oxidation) was shown to increase glucose oxidation/glycolysis ratio restoring mitochondrial functions and related molecular abnormalities in vitro and to decrease PA pressure, right ventricular hypertrophy and muscularization of small PAs in several PAH models.71

Recent discoveries have highlighted that the morphology of subcellular distribution of mitochondria differs between PAH and control cells. Compared to control cells, mitochondria of PAH cells are often clustered perinuclearly. This subcellular organization of mitochondria may represent a major component of the stress response. Indeed, hypoxia was found to trigger microtubule-dependent accumulation of mitochondria in close proximity to the nucleus of PAECs, resulting in elevated levels of reactive oxygen species (ROS) in the nucleus and increased binding of HIF-1α to the VEGF promoter.72 Moreover, this perinuclear positioning of mitochondria may facilitate the transfer of substrates, co-factors, and complex from the mitochondria to the nucleus leading to epigenetic modifications that remodel the chromatin, influence gene transcription and contribute to stress adaptation.73

In healthy cells, mitochondria constantly divide and fuse to maintain mitochondrial functions. Mitochondrial fusion allows the exchange of contents including metabolites, proteins, and mitochondrial DNA. Such exchanges likely act as a defense mechanism buffering the effect of stress on mtDNA damage. However, mitochondrial fission is considered as a protective form of quality control mechanism by segregating damaged mitochondria from the healthy pool and their removal by mitophagy.74 Indeed, accumulation of dysfunctional mitochondria is directly associated with augmented cellular toxicity. In response to various factors, including activation of HIF-1α, mitochondria of PAH cells undergo fission and show a fragmented pattern; a feature also observed in various cancer cells.75,76 Inhibition of fission was associated with reduced cell proliferation, cell cycle arrest, and induction of apoptosis in vitro and regression of PAH in experimental models.77 Based on these data, it can be speculated that increased mitochondrial fission promotes mitophagy and that correction of the mitochondrial networking in PAH cells induces apoptosis secondary to inefficient clearance of dysfunctional mitochondria. However, further studies are needed to better understand the specific nature of the relationship between fusion/fission imbalance and PAH cell outcomes.

**Increased expression of anti-apoptotic proteins**

Acquisition of apoptosis-resistance of PAH cells is intimately linked to an imbalance between pro-apoptotic and
anti-apoptotic proteins. As observed in cancer cells, upregulation of Survivin, a member of the inhibitors of apoptosis protein (IAP) family is a hallmark of PAH cells, while undetectable in healthy cells.\textsuperscript{78} The deleterious role of the latter in vascular remodeling was illustrated by a study showing that intratracheal nebulization of an adenovirus carrying a phosphorylation-deficient Survivin mutant with dominant-negative properties reversed established MCT-induced PAH and prolonged survival.\textsuperscript{78} Accordingly, pharmacological inhibition of Survivin using YM155 was reported to improve PA pressure and right ventricular hypertrophy in rats exposed to chronic hypoxia.\textsuperscript{79} PAH-PASMCs are also characterized by an increased expression of the anti-apoptotic regulator B cell leukemia/lymphoma 2 (Bcl-2) and a diminished expression of the pro-apoptotic protein BIM.\textsuperscript{17,27} Similarly, over-expression of ARC (apoptosis repressor of CARD), an inhibitor of cell death, was also observed in remodeled vessels of patients with PAH as well as in rats in response to chronic hypoxia.\textsuperscript{80} Mice deficient for ARC also displayed attenuated chronic hypoxia-induced vascular remodeling and resistance to PH, underscoring the critical role of suppressed apoptosis in the development and progression of vascular lumen obliteration. Therefore, this disequilibrium between pro- and anti-apoptotic proteins is a hallmark of PAH-PASMCs contributing to resistance to apoptosis in stressful conditions.

**Role of ion channels**

Potassium ($K^+$) and calcium ($Ca^{2+}$) channels are pore-forming transmembrane proteins that regulate flow of ions across biological membranes and thus govern a plethora of biological processes including cell proliferation and apoptosis.\textsuperscript{81} Multiple studies have revealed that the deregulated expression of $K^+$ and $Ca^{2+}$ channels is associated with the development and progression of cancer and PAH.\textsuperscript{81,82} In addition to influence cell contractility, the reduced $K^+$ efflux in PAH-PASMCs secondary to suppression of voltage-gated potassium channels was accompanied by an elevation in the cytosolic $Ca^{2+}$ concentration protecting cells from apoptosis and supporting proliferation.\textsuperscript{81,83,84} The significance of decreased $K^+$ channels expression, particularly $K^+$ voltage-gated channel, shaker-related subfamily, member 5 (Kv1.5) in terms of disease progression, is illustrated by findings showing that restoration of the function of Kv1.5 in PAH-PASMCs or cancer cells promotes apoptosis and reduced PA medial hypertrophy in rats exposed to chronic hypoxia.\textsuperscript{16,85–87} The sustained elevation of the intracellular $Ca^{2+}$ concentration in PAH-PASMCs, due to $K^+$ channels dysfunction coupled with excessive expression of transient receptor potential-canonical (TRPC) channels, has been documented to exert stimulating effects on the calciuminur signaling that boosts the capacity of the cells to resist to death.\textsuperscript{17,78,88} Interestingly, the loss of mitochondrial uncoupling protein 2 (UCP2) in control PASMCs was reported to cause a profound decline in the entry of $Ca^{2+}$ from the endoplasmic reticulum to the mitochondria, that in turn led to a reduction in the activity of pyruvate dehydrogenase, suppression of mitochondrial function, activation of HIF1α and NFAT, and resistance to cell apoptosis.\textsuperscript{67} In a similar fashion, increased expression of miR-25 and miR-138 in PAH-PASMCs was found to directly downregulate expression of mitochondrial $Ca^{2+}$ uniporter (MCU) leading to reduced intramitochondrial concentration of $Ca^{2+}$ and promotion of Warburg effect.\textsuperscript{89} Based on these findings, reduced intramitochondrial $Ca^{2+}$ concentration appears as one of the mechanism used by PAH-PASMCs to acquire a cancer-like phenotype.

**Genetic predisposition/susceptibility: role of BMPR2**

It has been recognized for a long time that some gene variants or mutations can cause a predisposition to cancer.\textsuperscript{90} For example, mutations in BRCA1 or BRCA2 genes greatly increase a person’s risk of developing breast cancer. BMPR2 pathogenic variant is the most common genetic risk factor for PAH development, accounting for approximately 25% of idiopathic PAH and the majority of hereditary cases.\textsuperscript{91,92} Patients carrying a BMPR2 mutation are generally younger at diagnosis and have more severe disease.\textsuperscript{92} Under basal conditions, mice heterozygous for Bmpr2 do not develop PH. Nevertheless, exposition to these mice to hypoxia or inflammatory stress leads to exacerbation of PH compared to wild-type mice.\textsuperscript{93,94} These findings, along with genetic studies reporting low penetrance of PAH among carriers of a BMPR2 mutation suggest that additional factors (the so-called “second-hit” hypothesis) required for the disease expression. In a similar way, loss of Bmpr2 function in mice expressing the mouse mammary tumor virus Polyoma virus middle T antigen (MMTV.PyVmT) was shown to increase tumor metastasis.\textsuperscript{95} Mechanistically, reduced BMPR2 signaling in PAH cells was shown to promote the recruitment of inflammatory cells and endothelial-to-mesenchymal transition and to impair mitochondrial function,\textsuperscript{98} cooperatively contributing to endothelial cell dysfunction, cell demise, and occlusive vascular remodeling.\textsuperscript{99} Importantly, Ataluren, a drug that permits ribosomal read through of premature stop codons and shown to induce full-length functional dystrophin in the mdx mouse model of Duchenne muscular dystrophy,\textsuperscript{100} was able to correct BMP signaling in vitro suggesting that this compound could be proposed as a new personalized therapy for a subgroup of PAH patients harboring BMPR2 nonsense mutations.\textsuperscript{101} It must keep in mind that contrary to cancer in which a wide array of mutations have been identified as predisposing factors, evidence on the contribution of genes to the hereditary predisposition to PAH is limited.

**Epigenetic alterations**

Major mechanisms of epigenetic regulation are DNA methylation, histone modification, and RNA interference.
It is now widely accepted that epigenetic abnormalities are key drivers of both cancer and PAH development. While no mutation of SOD2 gene has been found in PAH, reduced expression of the latter is a common feature of PASMCs from PAH patients and animal models. Genomic bisulfite sequencing has demonstrated selective hypermethylation of CpG island in the intronic and promoter sequences of the SOD2 gene in PASMCs from Fawn-Hooded rats (FHR, a strain that spontaneously develops PH with age). Importantly, the reversal of SOD2 hypermethylation by the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine was documented to restore both SOD2 expression and the ratio of PASMCs proliferation to apoptosis underscoring an epigenetic component in PAH pathogenesis. Along with DNA methylation changes, reversible acetylation of histones, governed by the opposite action of histone acetyltransferases (HAT) and histone deacetylases (HDAC), has emerged as an important post-translational modification that regulates chromatin structure and gene expression. In PAH, over-expression of nuclear-located HDAC1, 2, and 4 has been detected in human lung extracts from idiopathic PAH patients compared to controls, suggesting that epigenetic changes that accompanied these differential expressions contribute to the structural anomalies seen in the disease. Intimately linked to proteins that incorporate histone marks are those implicated in their interpretation. A member of the bromodomain and extra-terminal motif (BET) protein family called bromodomain protein 4 (BRD4) was recently found to be upregulated in PAH-PASMCs affecting the expression level of Survivin, NFATc2 and Bcl-2. The over-expression of BRD4 was shown to result from the downregulation of miR-204. Micro RNA (miRNA) are fundamental epigenetic components that repress translation and/or induce mRNA degradation in interacting with complementary sequences found in the 3' untranslated transcribed region of target mRNAs. In addition to miR-204, the aberrant expression of a handful of miRNAs has been related to PAH and cancer. For instance, several studies have provided convincing experimental evidence that the miR-17-92 cluster is a bona fide oncogene. In PAH, BMPR2 was identified as a direct target of miR-17-5p and miR-20a and genetic inactivation of miR-17-92 in smooth muscle cells conferred protection against hypoxia-induced PH in mice. Consistently, pharmacological inhibition of miR-17 using antagonirs was demonstrated to improve lung and heart function in experimental PAH. Although the contribution of epigenetic alterations in the development and progression of PAH is still poorly understood, epigenetic targets offer therapeutic potential.

**Overview of therapeutic strategies used in cancer to treat PAH**

Although great strides in treatment and care have been made, current therapies principally devoted to reverse the sustained vasoconstriction fail to reverse PAH and only result in a modest improvement in the morbidity and mortality. In the face of this reality, it is important to consider new therapies targeting alternative pathways such as those implicated in vascular remodeling. The numerous similarities between cancer cells and PAH cells have opened to the possibility of exploiting therapeutic strategies used in cancer to combat PAH (Fig. 4). Taking into account that PAH is most frequently diagnosed when patients have reached a more advanced stage of the disease, therapies aiming to stop the proliferation and to induce cell death in remodeled vessels appear to be fully justified.

**Tyrosine kinase inhibitors**

Chemotherapy is commonly used as a front-line therapy for cancer. Tyrosine kinases inhibitors, including Imatinib and Dasatinib, have been successfully employed in the treatment of chronic myeloid leukemia. In addition to inhibit the BCR-ABL kinase, these inhibitors target other tyrosine kinases including c-KIT and PDGF receptor. Because c-KIT-positive cells infiltrate remodeled vessels and PDGF expression is elevated in lung biopsies of PAH patients, studies were undertaken to evaluate the therapeutic benefits of Imatinib and its derivative in preclinical models. Imatinib treatment demonstrated remarkable efficacy in several experimental models with established PAH, reducing right ventricular systolic pressure and hypertrophy, medial wall thickness, and mortality. Similar results were obtained with Dasatinib. Despite these remarkable results achieved in pre-clinical PAH models, mixed results were obtained in humans. Results from clinical trials indicated that Imatinib is effective in improving exercise capacity, pulmonary hemodynamics, and echocardiographic measures as add-on therapy in patients with severe PAH. Nevertheless, the risk of clinical worsening was enhanced in Imatinib-treated patients likely because of adverse effects. Notably, cardiotoxicity and occurrence of subdural hematoma in PAH-treated patients has tempered the positive reports, discouraging the use of these compounds in PAH. Moreover, development of PAH was reported in some patients treated for Dasatinib for chronic myeloid leukemia. In experimental models, treatment or rats with Dasatinib or Imatinib did not induce PAH. However, Dasatinib, but not Imatinib, pretreated rats developed an exaggerated response to MCT or chronic hypoxia-induced PH, indicating that Dasatinib can predispose to PAH development. Based on these data, tyrosine kinase inhibitors remain a promising tool in the rescue armamentarium for PAH. The beneficial hemodynamic effects of Imatinib in a patient subset support the need to identify individual factors that predict a positive or negative response to this drug.

**Alkylating agents**

Although Harbaum et al. reported a case in which PAH was completely resolved following cytotoxic treatment
including cyclophosphamide, doxorubicin, and etoposide regimen, exposure to these chemotherapeutic agents was identified as a risk factor for the development of PH in human. On the basis of these findings, the consequences of alkylating agents’ exposure on the pulmonary vasculature were explored in several species. In all the tested species, cyclophosphamide was shown to induce severe PH in mice associated with pulmonary venous remodeling reminiscent of pulmonary veno-occlusive disease (PVOD), an uncommon form of PH. In direct connection with this, mitomycin-C therapy was also identified as a potent inducer of PVOD in humans and rats, further supporting the fact that, in the early stage of the disease, DNA damaging agents pose a significant genomic stress contributing to endothelial cell apoptosis and PAH development, but in advanced stages of the disease, it may induce stress overload of the DDR pathway, improving vascular remodeling. Nevertheless, the current evidence suggests that there is no place for these agents in PAH therapy.

**mTOR inhibitors**

The evidence linking activated mTOR signaling to PAH have engendered significant interest in targeting this pathway for PAH therapy. Rapamycin (Sirolimus), a macrolide immunosuppressant and preferential mTORC1 inhibitor, was used in experimental PAH leading to mitigated results. Indeed, rapamycin failed to demonstrate beneficial effects in terms of survival, pulmonary hemodynamics, vascular remodeling, and right ventricular hypertrophy in the MCT model. These results contrast with those reporting curative effects of high doses of rapamycin or PP242 (a more effective mTORC1 inhibitor than rapamycin) in MCT-induced PAH and chronic hypoxia-induced PH in rats, respectively. A pilot study was conducted to assess the safety and efficacy of Everolimus (an oral antineoplastic agent derived from rapamycin and approved for various conditions such as prevention of organ rejection after transplant) in patients suffering from PAH or chronic thromboembolic PH with very limited exercise capacity.

**Fig. 4 Pathogenic concepts of PAH.** Like cancer cells, PAH cells are exposed to stressful conditions. To deal with these insults causing initial cell death, PAH cells have developed adaptive mechanisms allowing them to survive and proliferate over time and leading to vascular remodeling of distal pulmonary arteries. Given that PAH and cancer cells share numerous similarities, therapeutic strategies used in cancer are exploited to treat PAH. “Anticancer” drugs showing beneficial effects in experimental PAH models and are tested in PAH clinical trials are highlighted within the dotted boxes.
Treatment with Everolimus was safe and tolerable and resulted in a significant decrease in PVR and an increase in 6-minute walk distance. These preliminary results may justify its formal evaluation in future clinical trials.

Tacrolimus

Using a high-throughput assay to screen over 3500 FDA-approved drugs and bioactive compounds for induction of BMPR2 signaling, Spierkerkoetter et al. identified Tacrolimus (FK506), a calcineurin inhibitor and immunosuppressant used following solid organ transplantation. The therapeutic benefit of low-dose Tacrolimus was demonstrated in multiple experimental PAH models. Interestingly, a clinical benefit was reported following the compassionate use of low-dose FK506 in three end-stage PAH patients. In all patients, FK506 treatment was associated with stabilization in cardiac function, freedom from hospitalization for right ventricular failure, and upregulation of BMPR2 expression in peripheral blood mononuclear cells. On the basis on these findings, a randomized, double-blind, placebo-controlled trial is ongoing to evaluate the safety and tolerability of FK506 in stable patients with PAH.

Dichloroacetate

Molecules that stimulate mitochondrial respiration are expected to enhance the production of ROS in mitochondria and to induce mitochondria-dependent apoptosis in diseased cells, sparing control cells. In direct connection with this, it has been demonstrated that dichloroacetate (DCA), which inhibits pyruvate dehydrogenase kinase (PDK) causing elevation of oxidative phosphorylation and ROS production, directly induces cancer cells and PAH-PASMCs apoptosis without impacting control cells. DCA was shown to regress established PAH in FHR rats and MCT-induced PH rats, as well as in mice over-expressing the serotonin transported targeted to smooth muscle cells. Based on positive effects on animal models, the safety, tolerability, and effectiveness of DCA is currently studied in patients with moderate-to-severe PAH despite background therapy (NCT01083524).

Epigenetics-based therapies

Understanding epigenetic mechanisms arouses a growing interest in various diseases, as it may serve as a new therapeutic approach. Indeed, epigenetic modifications do not change the genetic program but just refer to a differential genome lecture that is reversible. Although the overall status of histone modification is largely unknown in PAH, class I and IIa HDAC inhibitors have also been exploited in PAH for their beneficial effects under several pathophysiological conditions like cancer and inflammation related pathologies. These investigations have yielded mixed results. Indeed, studies conducted in rats exposed to chronic hypoxia have reported positive impact of class I or pan-HDAC inhibitors on pulmonary vascular remodeling. Conversely, suppression of HDACs had no therapeutic or beneficial effect in the SU5416/hypoxia-exposed rat model or was accompanied by a deterioration of the right ventricular function in a rat model of right ventricular hypertrophy. Given the unresolved controversies highlighted by these works and concerns regarding the unforeseeable pleiotropic epigenetic effects caused by these inhibitors, the potential utility of HDAC inhibitors in PAH need further evaluation by either genetic manipulation or more selective HDAC inhibitors.

The epigenetic sensor BRD4 that recognizes and binds acetylated histones influencing chromatin remodeling and gene expression has emerged as a promising drug target in multiple hyperproliferative disorders. As documented in many cancer types, BRD4 was found to be upregulated in PAH-PASMCs sustaining cell survival and proliferation. More importantly, molecular and pharmacological inhibition of BRD4 reversed established PAH in the Sugen/hypoxia rat model, suggesting that BRD4 inhibitors currently tested in clinical trials for cancer may offer a new therapeutic perspective for PAH patients. Finally, miRNAs represent an additional layer of regulation of gene expression. Among the miRNAs involved in the pathogenesis of PAH, many of them have been associated with cancer. Although many miRNAs with therapeutic value in PAH have been discovered, microRNA-based therapies are still in their infancy and potential adverse effects need to be evaluated.

Summary

In contrast to the earlier belief that vasoconstriction plays a key role in PAH pathogenesis, it is now clearly established that excessive proliferation and resistance to apoptosis of fibroblasts, PASMCs and PAECs are pivotal components of pulmonary vascular remodeling. Due to the long list of pathogenic analogies between cancer and PAH (Fig. 2), the use of antineoplastic drugs in combination with vasodilators seem to be a promising way to tackle established PAH. Nevertheless, although apoptosis-based therapies represent an attractive avenue to regress vascular lesions in PAH, their non-selectivity remains a major limitation, as they cannot differentiate healthy cells from diseased cells, leading to important side effects limiting their utilization. To circumvent this problem, identifying a biochemical feature specific to PAH cells (i.e. lacking in normal cells) with key network properties resulting in a combinatorial attack on multiple signaling pathways implicated in PAH pathogenesis and leading to programmed cell death is critical.

Conflict of interest

The author(s) declare that there is no conflict of interest.
Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References
1. Lajoie AC, Lauziere G, Lega JC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med 2016; 4(4): 291–305.
2. Voelkel NF, Cool C, Lee SD, et al. Primary pulmonary hypertension between inflammation and cancer. Chest 1998; 114(Suppl. 3): 225S–230S.
3. Guignabert C, Tu L, Le Hiress M, et al. Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur Respir Rev 2013; 22(130): 543–551.
4. Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54(Suppl. 1): S10–19.
5. Rabinovitch M, Guignabert C, Humbert M, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 2014; 115(1): 165–175.
6. Shalapour S and Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 2015; 125(9): 3347–3355.
7. Humbert M, Monti G, Boren F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151(5): 1628–1631.
8. Selimovic N, Bergh CH, Andersson B, et al. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009; 34(3): 662.
9. Savale L, Tu L, Rideau D, et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 2009; 10(1): 6.
10. Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009; 104(2): 236.
11. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11(3): 554.
12. Izikki M, Guignabert C, Fadel E, et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 2009; 119(3): 512–523.
13. Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014; 14(11): 736–746.
14. Paulin R, Courboulin A, Meloche J, et al. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 2011; 123(11): 1205–1215.
15. Bonnet S, Belus A, Hyvelin JM, et al. Effect of chronic hypoxia on agonist-induced tone and calcium signaling in rat pulmonary artery. Am J Physiol Lung Cell Mol Physiol 2001; 281(1): L193–201.
16. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K⁺ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11(1): 37–51.
17. Bonnet S, Rochefort G, Sutendra G, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A 2007; 104(27): 11418–11423.
18. Goel HL and Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013; 13(12): 871–882.
19. Tuder RM, Chacon M, Alger L, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 2001; 195(3): 367–374.
20. Hirose S, Hosoda Y, Furuya S, et al. Expression of vascular endothelial growth factor and its receptors correlates closely with formation of the plexiform lesion in human pulmonary hypertension. Pathol Int 2000; 50(6): 472–479.
21. Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001; 15(2): 427–438.
22. Partovian C, Adnot S, Raffestin B, et al. Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am J Respir Cell Mol Biol 2000; 23(6): 762–771.
23. Savai R, Al-Tamari HM, Sedding D, et al. Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. Nat Med 2014; 20(11): 1289–1300.
24. Dansen TB and Burgering BMT. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol 2008; 18(9): 421–429.
25. Laplante M and Sabatini David M. mTOR signaling in growth control and disease. Cell 2012; 149(2): 274–293.
26. Goncharova EA. mTORC and vascular remodeling in lung diseases: current challenges and therapeutic prospects. FASEB J 2013; 27(5): 1796–1807.
27. Goncharov DA, Kudryashova TV, Ziai H, et al. Mammalian target of rapamycin complex 1 gene deletion in smooth muscle activates mammalian target of rapamycin signaling and induces pulmonary hypertension. Am J Respir Cell Mol Biol 2016; 55(3): 352–367.
28. Zanconato F, Forcato M, Battilana G, et al. Genome-wide mechanoactivation of the YAP/TAZ-miR-130/301 circuit. Proc Natl Acad Sci U S A 2007; 104(27): 11418–11423.
29. Ehmer U and Sage J. Control of proliferation and cancer growth by the hippo signaling pathway. Nat Rev Cancer 2013; 13(12): 871–882.
30. Van Marle H, Rozier H, Remacle B, et al. Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am J Respir Cell Mol Biol 2000; 23(6): 762–771.
31. Zanconato F, Forcato M, Battilana G, et al. Genome-wide mechanoactivation of the YAP/TAZ-miR-130/301 circuit. Proc Natl Acad Sci U S A 2007; 104(27): 11418–11423.
32. Zanconato F, Forcato M, Battilana G, et al. Genome-wide mechanoactivation of the YAP/TAZ-miR-130/301 circuit. Proc Natl Acad Sci U S A 2007; 104(27): 11418–11423.
33. Zanconato F, Forcato M, Battilana G, et al. Genome-wide mechanoactivation of the YAP/TAZ-miR-130/301 circuit. Proc Natl Acad Sci U S A 2007; 104(27): 11418–11423.
34. Zanconato F, Forcato M, Battilana G, et al. Genome-wide mechanoactivation of the YAP/TAZ-miR-130/301 circuit. Proc Natl Acad Sci U S A 2007; 104(27): 11418–11423.
35. Zanconato F, Forcato M, Battilana G, et al. Genome-wide mechanoactivation of the YAP/TAZ-miR-130/301 circuit. Proc Natl Acad Sci U S A 2007; 104(27): 11418–11423.
34. Kudryashova TV, Goncharov DA, Pena A, et al. HIPPO–Integrin-linked kinase cross-talk controls self-sustaining proliferation and survival in pulmonary hypertension. *Am J Respir Crit Care Med* 2016; 194(7): 866–877.

35. Boucherat O, Bonnet S and Paulin R. The HIPPO-Thesis of Pulmonary HYPERTension. *Am J Respir Crit Care Med* 2016; 194(7): 787–789.

36. Levine AJ. p53, the cellular gatekeeper for growth and division. *Cell* 1997; 88(3): 323–331.

37. Mizuno S, Boggaard HJ, Kraskauskas D, et al. p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. *Am J Physiol Lung Cell Mol Physiol* 2011; 300(5): L753–L761.

38. Mouraret N, Marcos E, Abid S, et al. Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension. *Circulation* 2013; 127(16): 1664–1676.

39. Voukddan KH and Ryan KM. p53 and metabolism. *Nat Rev Cancer* 2009; 9(10): 691–700.

40. Meek DW. Tumour suppression by p53: a role for the DNA damage response? *Nat Rev Cancer* 2009; 9(10): 714–723.

41. Hanahan D and Weinberg Robert A. Hallmarks of cancer: the cancer cell's Achilles' heel. *Cell* 2011; 144(5): 646–674.

42. Xu L, Li S and Stohr BA. The role of telomere biology in pulmonary hypertension. *Crit Care Med* 2014; 50(6): 1118–1128.

43. Shen T, Ma J, Zhang L, et al. Positive feedback-loop of telomerase reverse transcriptase and 15-lipoxygenase-2 promotes pulmonary hypertension. *PLoS One* 2013; 8(12): e83132.

44. Mouraret N, Houssaini A, Abid S, et al. Role for telomerase in pulmonary arterial hypertension. *Nat Rev Cancer* 2010; 10(4): 267–277.

45. Boucherat O, Bonnet S and Paulin R. The HIPPO-Thesis of Pulmonary HYPERTension. *Am J Respir Crit Care Med* 2016; 194(7): 787–789.

46. Masutomi K, Possemato R, Wong JM, et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage signaling in pulmonary arterial hypertension. *Cell Metab* 2015; 112(8): 1942–1943.

47. Meloche J, Le Guen M, Potus F, et al. Telomere maintenance is a critical determinant in the physiopathology of pulmonary hypertension. *J Am Coll Cardiol* 2015; 66(17): 1942–1943.

48. Xu L, Li S and Stohr BA. The role of telomere biology in cancer. *Annu Rev Pathol* 2013; 8: 49–78.

49. Shen T, Ma J, Zhang L, et al. Positive feedback-loop of telomerase reverse transcriptase and 15-lipoxygenase-2 promotes pulmonary hypertension. *PLoS One* 2013; 8(12): e83132.

50. Li M, Vattulainen S, Aho J, et al. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension. *Am J Respir Cell Mol Biol* 2014; 50(6): 1118–1128.

51. de Jesus Perez VA, Yuan K and Lyuksyutova MA. Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2014; 189(10): 1260–1272.

52. Ngo J, Matsuyama M, Kim C, et al. Bax deficiency extends the survival of Ku70 knockout mice that develop lung and heart diseases. *Cell Death Dis* 2015; 6(3): e1706.

53. Ranchoux B, Meloche J, Paulin R, et al. DNA damage and pulmonary hypertension. *Int J Mol Sci* 2016; 17(6): 990.

54. Zhang J, de Toledo SM, Pandey BN, et al. Role of the translationally controlled tumor protein in DNA damage sensing and repair. *Proc Natl Acad Sci U S A* 2012; 109(16): E926–933.

55. Lavoie JR,Ormiston ML, Perez-Iratxeta C, et al. Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension. *Circulation* 2014; 129(21): 2125–2135.

56. Wang GK, Li SH, Zhao ZM, et al. Inhibition of heat shock protein 90 improves pulmonary arteriolar remodeling in pulmonary arterial hypertension. *Oncotarget* 2016; 7(34): 54263–54273.

57. Lee S-J, Smith A, Guo L, et al. Autophagic protein LC3B confers resistance against hypoxia-induced pulmonary hypertension. *Am J Respir Crit Care Med* 2011; 183(5): 649–658.

58. Long L, Yang X, Southwood M, et al. Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. *Circ Res* 2013; 112(8): 1159–1170.

59. Kim SY, Lee JH, Huh JW, et al. Bortezomib alleviates experimental pulmonary arterial hypertension. *Am J Respir Cell Mol Biol* 2012; 47(5): 698–708.

60. Ibrahim YF, Wong CM, Pavlickova L, et al. Mechanism of the susceptibility of remodeled pulmonary vessels to drug-induced cell killing. *J Am Heart Assoc* 2014; 3(1): e000520.

61. Wang X, Ibrahim YF, Das D, et al. Carfilzomib reverses pulmonary arterial hypertension. *Cardiovasc Res* 2016; 110(2): 188–199.

62. Kroemer G and Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. *Cancer Cell* 2008; 13(6): 472–482.

63. Paulin R and Michelakis ED. The metabolic theory of pulmonary arterial hypertension. *Circ Res* 2014; 115(1): 148–164.

64. Sutendra G and Michelakis ED. The metabolic basis of pulmonary arterial hypertension. *Cell Metab* 2014; 19(4): 558–573.

65. Li M, Riddle S, Zhang H, et al. Metabolic reprogramming regulates the proliferative and inflammatory phenotype of adventitial fibroblasts in pulmonary hypertension through the transcriptional corepressor C-terminal binding protein-1. *Circulation* 2016; 134(15): 1105–1121.

66. Plecita-Hlavata L, Tauber J, Li M, et al. Constitutive repression of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. *Circ Res* 2013; 112(8): 1159–1170.

67. Dromparis P, Paulin R, Sutendra G, et al. Uncoupling protein 2 deficiency mimics the effects of hypoxia and endoplasmic reticulum stress on mitochondria and triggers pseudohypoxic pulmonary vascular remodeling and pulmonary hypertension. *Circ Res* 2013; 113(2): 126–136.

68. Sutendra G, Dromparis P, Wright P, et al. The role of Nogo protein type II receptor degradation. *Circ Res* 2013; 112(8): 1159–1170.

69. Tennant DA, Duran RV and Gottlieb E. Targeting metabolic transformation for cancer therapy. *Nat Rev Cancer* 2010; 10(4): 267–277.

70. Sutendra G, Bonnet S, Rochefort G, et al. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. *Sci Transl Med* 2010; 2(4): 44ra58–44ra59.

71. Al-Mehdi AB, Pastukh VM, Swiger BM, et al. Perinuclear mitochondrial clustering creates an oxidant-rich nuclear...
domain required for hypoxia-induced transcription. *Sci Signal* 2012; 5(231): ra47.

73. Boukouris AE, Zervopoulos SD and Michelakis ED. Metabolic enzymes moonlighting in the nucleus: metabolic regulation of gene transcription. *Trends Biochem Sci* 2016; 41(8): 712–730.

74. Youle RJ and van der Bliek AM. Mitochondrial fission, fusion, and stress. *Science* 2012; 337(6098): 1062–1065.

75. Rehman J, Zhang HJ, Toth PT, et al. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. *FASEB J* 2012; 26(5): 2175–2186.

76. Ryan JJ, Marsboom G, Fang YH, et al. PGClalpha-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2013; 187(8): 865–878.

77. Marsboom G, Toth PT, Ryan JJ, et al. Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. *Circ Res* 2012; 110(11): 1484–1497.

78. McMurtry MS, Archer SL, Altieri DC, et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. *J Clin Invest* 2005; 115(6): 1479–1491.

79. Fan Z, Liu B, Zhang S, et al. YM155, a selective survivin inhibitor, reverses chronic hypoxia pulmonary hypertension in rats via upregulating voltage-gated potassium channels. *Clin Exp Hypertens* 2015; 37(5): 381–387.

80. Zaiman AL, Damico R, Thoms-Chesley A, et al. A critical role for the protein apoptosis repressor with caspase recruitment domain in hypoxia-induced pulmonary hypertension. *Circulation* 2011; 124(23): 2533–2542.

81. Boucherat O, Chabot S, Antigny F, et al. Potassium channels in pulmonary arterial hypertension. *Eur Respir J* 2015; 46(4): 1167–1177.

82. Litan A and Langhans SA. Cancer as a channelopathy: ion channels and pumps in tumor development and progression. *Front Cell Neurosci* 2015; 9: 86.

83. Archer SL, Wu XC, Thebaud B, et al. Preferential expression and function of voltage-gated, O2-sensitive K+ channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells. *Circ Res* 2004; 95(3): 308–318.

84. Kuhr FK, Smith KA, Song MY, et al. New mechanisms of pulmonary arterial hypertension: role of Ca(2)(+) signaling. *Am J Physiol Heart Circ Physiol* 2012; 302(8): H1546–1562.

85. Wang J, Juhaszova M, Rubin LJ, et al. Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells. *J Clin Invest* 1997; 100(9): 2347–2353.

86. Pozeg Zl, Michelakis ED, McMurtry MS, et al. In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. *Circulation* 2003; 107(15): 2037–2044.

87. Remillard CV and Yuan JX. Activation of K+ channels: an essential pathway in programmed cell death. *Am J Physiol Lung Cell Mol Physiol* 2004; 286(1): L49–67.

88. Alzoubi A, Almalouf P, Toba M, et al. TRPC4 inactivation confers a survival benefit in severe pulmonary arterial hypertension. *Am J Pathol* 2013; 183(6): 1779–1788.

89. Hong Z, Chen KH, Dasgupta A, et al. miR-138 and miR-25 downregulate MCU, causing pulmonary arterial hypertension’s cancer phenotype. *Am J Respir Crit Care Med* 2017; 195(4): 515–529.

90. Rahman N. Realizing the promise of cancer predisposition genes. *Nature* 2014; 505(7483): 302–308.

91. Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. *J Am Coll Cardiol* 2013; 62(Suppl. 25): D13–21.

92. Evans JD, Girerd B, Montani D, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. *Lancet Respir Med* 2016; 4(2): 129–137.

93. Song Y, Jones JE, Beppu H, et al. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. *Circulation* 2005; 112(4): 553–562.

94. Frank DB, Lowery J, Anderson L, et al. Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature. *Am J Physiol Lung Cell Mol Physiol* 2008; 294(1): L98–109.

95. Owens P, Pickup MW, Novitskiy SV, et al. Disruption of bone morphogenic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. *Proc Natl Acad Sci U S A* 2012; 109(8): 2814–2819.

96. Sawada H, Saito T, Nickel NP, et al. Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension. *J Exp Med* 2014; 211(2): 263–280.

97. Hopper RK, Moonen JR, Diebold I, et al. In pulmonary arterial hypertension, reduced BMPR2 promotes endothelial-to-mesenchymal transition via HMGA1 and its target slug. *Circulation* 2016; 133(18): 1783–1794.

98. Diebold I, Hennigs JK, Miyagawa K, et al. BMPR2 preserves mitochondrial function and DNA integrity during reoxygenation to promote endothelial survival and reverse pulmonary hypertension. *Cell Metab* 2015; 21(4): 596–608.

99. Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. *Circ Res* 2006; 98(2): 209–217.

100. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic modulators, modifiers and mediators in cancer aetiology mechanism to therapy. *Cell* 2012; 150(1): 12–27.

101. Drake KM, Dunmore BJ, McNelly LN, et al. Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension. *Am J Respir Cell Mol Biol* 2013; 49(3): 403–409.

102. Gamen E, Seeger W and Pullamsetti SS. The emerging role of epigenetics in pulmonary hypertension. *Eur Respir J* 2015; 48(3): 903–917.

103. Dawson MA and Kouzarides T. Cancer epigenetics: from gene regulation of gene transcription. *Trends Biochem Sci* 2007; 32(3): 90–97.

104. Feinberg AP, Koldobskiy MA and Gondor A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. *Nat Rev Genet* 2016; 17(5): 284–299.

105. Archer SL, Marsboom G, Kim GH, et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 (SOD2) in pulmonary arterial hypertension: a basis for excessive cell
proliferation and a new therapeutic target. *Circulation* 2010; 121(24): 2661–2671.

106. Zhao L, Chen C-N, Haji N, et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA). *Circulation* 2012; 126(4): 455–467.

107. Meloche J, Potus F, Vaillancourt M, et al. Bromodomain-containing protein 4: the epigenetic origin of pulmonary arterial hypertension. *Circ Res* 2015; 117(6): 525–535.

108. Courboulin A, Paulin R, Giguerre NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. *J Exp Med* 2011; 208(3): 535–548.

109. Courboulin A, Ranchoux B, Cohen-Kaminsky S, et al. MicroRNA networks in pulmonary arterial hypertension: share mechanisms with cancer? *Curr Opin Oncol* 2016; 28(1): 72–82.

110. Chun HJ, Bonnet S and Chan SY. Translating microRNA biology in pulmonary hypertension: it will take more than “miR” words. *Am J Respir Crit Care Med* 2017; 195(2): 167–178.

111. Boucherat O, Potus F and Bonnet S. microRNA and pulmonary hypertension. *Adv Exp Med Biol* 2015; 888: 237–252.

112. He L, Thomson JM, Hemann MT, et al. A microRNA poly-cistron as a potential human oncogene. *Nature* 2005; 435(7043): 828–833.

113. Brock M, Trenkmann M, Gay RE, et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. *Circ Res* 2009; 104(10): 1184–1191.

114. Chen T, Zhou G, Zhou Q, et al. Loss of microRNA-17 approximately 92 in smooth muscle attenuates experimental pulmonary hypertension via induction of PDZ and LIM domain 5. *Am J Respir Crit Care Med* 2015; 191(6): 678–692.

115. Pullamsetti SS, Doebele C, Fischer A, et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. *Am J Respir Crit Care Med* 2012; 185(4): 409–419.

116. Stagno F, Stella S, Spitaleri A, et al. Imatinib mesylate in pulmonary arterial hypertension. *Adv Exp Med Biol* 2015; 888: 237–252.

117. He L, Thomson JM, Hemann MT, et al. A microRNA poly-cistron as a potential human oncogene. *Nature* 2005; 435(7043): 828–833.

118. Chen T, Zhou G, Zhou Q, et al. Loss of microRNA-17 approximately 92 in smooth muscle attenuates experimental pulmonary hypertension via induction of PDZ and LIM domain 5. *Am J Respir Crit Care Med* 2015; 191(6): 678–692.

119. Pullamsetti SS, Doebele C, Fischer A, et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. *Am J Respir Crit Care Med* 2012; 185(4): 409–419.

120. Pullamsetti SS, Berghausen EM, Dbabra L, et al. Role of Src tyrosine kinases in experimental pulmonary hypertension. *Arterioscler Thromb Vasc Biol* 2012; 32(6): 1354–1365.

121. Klein M, Schermuly RT, Ellinghaus P, et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. *Circulation* 2008; 118(20): 2081–2090.

122. Ghofrani HA, Seeger W and Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. *N Engl J Med* 2005; 353(13): 1412–1413.

123. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. *Am J Respir Crit Care Med* 2010; 182(9): 1171–1177.

124. Shah AM, Campbell P, Rocha QG, et al. Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension. *Eur Heart J* 2015; 36(10): 623–632.

125. Hoep MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. *Circulation* 2013; 127(10): 1128–1138.

126. Kerkela R, Grazzette L, Yacobi R, et al. Cardioxicity of the cancer therapeutic agent imatinib mesylate. *Nat Med* 2006; 12(8): 908–916.

127. Frost AE, Barst RJ, Hoep MM, et al. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. *J Heart Lung Transplant* 2015; 34(11): 1366–1375.

128. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. *Circulation* 2012; 125(17): 2128–2137.

129. Guignabert C, Phan C, Seferian A, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. *J Clin Invest* 2016; 126(9): 3207–3218.

130. Harbaum L, Hennigs JK, Baumann HJ, et al. Complete resolution of idiopathic pulmonary arterial hypertension following chemotherapy. *Eur Respir J* 2014; 43(5): 1513–1515.

131. Maeda K, Saiki Y and Yamaki S. In situ thrombosis of small pulmonary arteries in pulmonary hypertension: the rapamycin-atorvastatin-simvastatin study. *Am J Physiol Lung Cell Mol Physiol* 2007; 293(4): L933–940.

132. Ranchoux B, Gunther S, Quack R, et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. *Am J Pathol* 2015; 185(2): 356–371.

133. Perros F, Gunther S, Ranchoux B, et al. Mitomycin-induced pulmonary veno-occlusive disease: evidence from human disease and animal models. *Circulation* 2015; 132(9): 834–847.

134. McMurry MS, Bonnet S, Michelakis ED, et al. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamycin-atorvastatin-simvastatin study. *Am J Physiol Lung Cell Mol Physiol* 2015; 230846.

135. Houssaini A, Abid S, Mouraret N, et al. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. *Am J Respir Cell Mol Biol* 2013; 48(5): 568–577.

136. Seyfarth HJ, Hammerschmidt S, Halank M, et al. Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial. *Pulm Circ* 2013; 3(3): 632–638.

137. Spierektoetter E, Tian X, Cai J, et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. *J Clin Invest* 2013; 123(8): 3600–3613.

138. Spierektoetter E, Sung YK, Sudheendra D, et al. Low-dose FK506 (Tacrolimus) in end-stage pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2015; 192(2): 254–257.

139. Bonnet S, Michelakis ED, Porter CJ, et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary
arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. *Circulation* 2006; 113(22): 2630–2641.

140. McMurtry MS, Bonnet S, Wu X, et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. *Circ Res* 2004; 95(8): 830–840.

141. Guignabert C, Tu L, Izikki M, et al. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter. *FASEB J* 2009; 23(12): 4135–4147.

142. Bolden JE, Peart MJ and Johnstone RW. Anticancer activities of histone deacetylase inhibitors. *Nat Rev Drug Discov* 2006; 5(9): 769–784.

143. Cavasin MA, Demos-Davies K, Horn TR, et al. Selective class I HDAC inhibition suppresses hypoxia-induced cardiovascular remodeling through an anti-proliferative mechanism. *Circ Res* 2012; 110(5): 739–748.

144. De Raaf MA, Hussaini AA, Gomez-Arroyo J, et al. Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series). *Pulm Circ* 2014; 4(2): 237–243.

145. Bogaard HJ, Mizuno S, Hussaini AA, et al. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. *Am J Respir Crit Care Med* 2011; 183(10): 1402–1410.

146. Fu LL, Tian M, Li X, et al. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. *Oncotarget* 2015; 6(8): 5501–5516.

147. Mumby S, Gambaryan N, Meng C, et al. Bromodomain and extra-terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension. *Respirology* 2017; 22(1): 157–164.